- Conditions
- COPD, HIV/AIDS
- Interventions
- Proactive E-consult
- Behavioral
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 4 more
Location Directory
Clinical trials in Philadelphia, Pennsylvania
This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
17134
Shown on this page
12
Current sort
Recently updated
Location scope
Philadelphia, PA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 325–336 of 17,134 matching trials in Philadelphia, PA.
Live ClinicalTrials.gov results.
Institutions in Philadelphia
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more
- Conditions
- Intracranial Arteriosclerosis, Stroke
- Interventions
- Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management
- Drug · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 1,683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 114
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more
- Conditions
- Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
- Interventions
- Placebo, Inositol
- Other · Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- Hershey, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- ECMO
- Interventions
- Dose-escalation study of epoprostenol as adjunct anticoagulation in ECMO
- Drug
- Lead sponsor
- Garrett Keim
- Other
- Eligibility
- 0 Days to 17 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- Xanomeline/trospium chloride
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • Bellflower, California • Chino, California + 12 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
- Interventions
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 616 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
- Conditions
- Wide Neck Bifurcation Intracranial Aneurysms
- Interventions
- WEB
- Device
- Lead sponsor
- Microvention-Terumo, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 29
- States / cities
- Hollywood, Florida • Orlando, Florida • Honolulu, Hawaii + 22 more
- Conditions
- Progressive Supranuclear Palsy(PSP)
- Interventions
- AADvac1, LM11A-31
- Biological · Drug
- Lead sponsor
- Adam Boxer
- Other
- Eligibility
- 41 Years to 86 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- Sun City, Arizona • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Interventions
- Kidney Biopsy
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Up to 80 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2030
- U.S. locations
- 39
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
- Conditions
- Endometrial Cancer
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan, Cisplatin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 53
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Irvine, California + 47 more
- Conditions
- Ovarian Neoplasms, Ovarian Cancer
- Interventions
- Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • La Jolla, California • Walnut Creek, California + 29 more